TI
NVCR icon

Trexquant Investment’s NovoCure NVCR Stock Holding History

Trexquant Investment’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-69,148
Closed -$893K – 1827
2025
Q3 		$893K Buy
+69,148
New +$924K 0.01% 1181
2024
Q4 		– Sell
-113,849
Closed -$1.78M – 1764
2024
Q3 		$1.78M Sell
113,849
-72,087
-39% -$1.31M 0.02% 852
2024
Q2 		$3.19M Sell
185,936
-92,402
-33% -$1.63M 0.05% 556
2024
Q1 		$4.35M Buy
278,338
+52,018
+23% +$765K 0.09% 354
2023
Q4 		$3.38M Buy
226,320
+159,755
+240% +$2.14M 0.08% 379
2023
Q3 		$1.08M Buy
+66,565
New +$1.92M 0.03% 725
2023
Q2 		– Sell
-3,986
Closed -$240K – 1685
2023
Q1 		$240K Sell
3,986
-272
-6% -$21.7K 0.01% 1270
2022
Q4 		$312K Buy
+4,258
New +$320K 0.01% 1087
2022
Q2 		– Sell
-6,840
Closed -$567K – 1751
2022
Q1 		$567K Sell
6,840
-23,011
-77% -$1.7M 0.03% 711
2021
Q4 		$2.24M Buy
29,851
+16,763
+128% +$1.68M 0.14% 184
2021
Q3 		$1.52M Buy
+13,088
New +$1.98M 0.12% 237
2021
Q2 		– Sell
-13,683
Closed -$1.81M – 1373
2021
Q1 		$1.81M Buy
+13,683
New +$2.16M 0.17% 163
2020
Q4 		– Sell
-15,147
Closed -$1.69M – 1355
2020
Q3 		$1.69M Sell
15,147
-5,905
-28% -$472K 0.11% 263
2020
Q2 		$1.25M Buy
21,052
+9,554
+83% +$628K 0.09% 331
2020
Q1 		$774K Buy
+11,498
New +$909K 0.06% 497
2019
Q4 		– Sell
-24,067
Closed -$1.8M – 1203
2019
Q3 		$1.8M Buy
+24,067
New +$1.92M 0.16% 183
2019
Q2 		– Sell
-32,438
Closed -$1.56M – 1024
2019
Q1 		$1.56M Buy
32,438
+25,310
+355% +$1.22M 0.11% 271
2018
Q4 		$239K Buy
+7,128
New +$261K 0.01% 855
2018
Q1 		– Sell
-25,648
Closed -$518K – 1287
2017
Q4 		$518K Buy
25,648
+14,958
+140% +$288K 0.06% 497
2017
Q3 		$212K Buy
+10,690
New +$210K 0.05% 610

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Trexquant Investment's NVCR Position: Q4 2025 in Review

Trexquant Investment sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 69,148 shares — an estimated $893K sold.

Trexquant Investment first reported a position in NVCR in Q3 2017 and held it in 20 quarters. The position peaked at $4.35M in Q1 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

  • Trexquant Investment reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
  • Trexquant Investment sold 69,148 NovoCure shares in Q4 2025, an estimated $893K.
  • Trexquant Investment first reported a position in NovoCure in Q3 2017 and held it in 20 quarters.
  • Trexquant Investment's NovoCure position peaked at $4.35M in Q1 2024.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Trexquant Investment's 13F filing for Q4 2025, filed 17 Feb 2026.